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O B J E C T I V E S The aim of this study was to noninvasively detect the anti-inﬂammatory properties
of the novel liver X receptor agonist R211945.
B A C KG ROUND R211945 induces reversal cholesterol transport and modulates inﬂammation in
atherosclerotic plaques. We aimed to characterize with 18F-ﬂuorodeoxyglucose (FDG)–positron emission
tomography (PET)/computed tomography (CT) and dynamic contrast-enhanced cardiac magnetic
resonance (DCE-CMR) inﬂammation and neovascularization, respectively, in atherosclerotic plaques with
R211945 treatment compared with atorvastatin treatment and a control.
METHOD S Twenty-one atherosclerotic New Zealand white rabbits were divided into 3 groups (control,
R211945 [3 mg/kg orally], and atorvastatin [3 mg/kg orally] groups). All groups underwent 18F-FDG–PET/CT
and DCE-CMR at baseline and at 1 and 3 months after treatment initiation. Concomitantly, serum
metabolic parameters and histology were assessed. For statistical analysis, continuous DCE-CMR and
PET/CT outcomes were modeled as linear functions of time by using a linear mixed model, whereas the
histological data, animal characteristics data, and nonlinear regression imaging data were analyzed with
a 2-tailed Student t test.
R E S U L T S 18F-FDG–PET/CT detected a decrease in mean and maximum standard uptake values (SUV)
over time in the R211945 group (both p 0.001), indicating inﬂammation regression. The atorvastatin group
displayed no signiﬁcant change (p  0.371 and p  0.600, respectively), indicating no progression or
regression. The control group demonstrated an increase in SUV (p  0.01 and p  0.04, respectively),
indicating progression. There was a signiﬁcant interaction between time and group for mean and maximum
SUV (p  0.0003 and p  0.0016, respectively) . DCE-CMR detected a trend toward difference (p  0.06) in
the area under the curve in the atorvastatin group, suggesting a decrease in neovascularization. There was
no signiﬁcant interaction between time and group (p  0.6350 and p  0.8011, respectively). Macrophage
and apolipoprotein B immunoreactivity decreased in the R211945 and atorvastatin groups (p  0.0001 and
p  0.0004, respectively), and R211945 decreased oxidized phospholipid immunoreactivity (p  0.02).
CONC L U S I O N S Noninvasive imaging with 18F-FDG–PET/CT and DCE-CMR and histological analysis
demonstrated signiﬁcant anti-inﬂammatory effects of the LXR agonist R211945 compared with atorvastatin.
The results suggest a possible role for LXR agonists in the treatment of atherosclerosis. (J Am Coll Cardiol
Img 2012;5:819–28) © 2012 by the American College of Cardiology Foundation
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820ardiovascular disease is the leading cause of
mortality worldwide (1). Atherosclerosis is
the primary cause of cardiovascular disease
and is caused by the accumulation of oxi-
ized lipids in the arterial wall that trigger the accu-
ulation of inflammatory cells, most prominently
acrophages (2,3). The ongoing recruitment of mac-
ophages leads to the formation of fatty streaks and
ltimately to the development of complex atheroscle-
otic plaques. Inflammation plays a central role in all
tages of atherosclerosis and, in particular, when ac-
ompanied by neovascularization, promotes athero-
clerotic plaque rupture and thrombosis, which cause
he majority of acute coronary events (4,5).
Currently, the mainstay for the treatment of
therosclerosis is the use of low-density lipoprotein
holesterol–lowering strategies, mainly statins,
which reduce the mortality risk by only
30% to 40% (6). Recently, strategies to
further lower risk have been actively ex-
plored (7). High-density lipoprotein cho-
lesterol displays a strong inverse relation-
ship with cardiovascular disease, as
demonstrated in multiple large epidemio-
logical studies including the Framingham
Heart Study (8). The mechanism by
which high-density lipoprotein exerts its
protective effects is mainly mediated by
reverse cholesterol transport (9), a process
by which peripheral tissue cells actively
excrete cholesterol and phospholipids
through the ATP-binding cassette trans-
porter A1 (ABCA1) leading to the forma-
tion of high-density lipoprotein. This pro-
cess is controlled by ABCA1 and is
directly regulated by liver X receptors
LXRs) (10). In animal models of atherosclerosis,
XR agonists attenuate the development and re-
erse existing atherosclerotic plaques (11,12). First-
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XR agonist, is a potent inducer of ABCA1 in
odents and cynomolgus monkeys without causing
iver and metabolic side effects.
We demonstrated previously that multimodality
olecular imaging using 18F-fluorodeoxyglucose
FDG)–positron emission tomography (PET)/
omputed tomography (CT) and dynamic contrast-
nhanced cardiac magnetic resonance (DCE-CMR)
as the ability to assess macrophage content/
nflammation and neovascularization in atheroscle-
otic plaques at baseline and after therapeutic inter-
ention (14–16). In this study, we aimed to assess
oninvasively with 18F-FDG–PET/CT and DCE-
CMR the effects of treatment with the LXR agonist
R211945 on macrophage content/inflammation
and neovascularization in atherosclerotic plaque
in a rabbit model of atherosclerosis and to char-
acterize its effects compared with treatment with
atorvastatin.
M E T H O D S
Animal model. Atherosclerosis was induced in 21
age- and weight-matched New Zealand White
rabbits (Charles River Laboratories, Wilmington,
Massachusetts) identically, as previously described
(14). After 4 months on a high-fat diet, the animals
were divided into 3 groups: a control group (n  9)
and 2 treatment groups (n  6 in each). The
nimals in the control group were kept on a
igh-fat diet only, and the animals in the treatment
roups were administered either R211945 (3 mg/kg
ody weight) or atorvastatin (3 mg/kg body weight)
ixed with the high-fat diet for 3 months (Fig. 1).
‡Department of Radiology, Mount Sinai School
, University of Cambridge, Cambridge, United
and Preventive Medicine, New York, New York;
ision, Daiichi Sankyo Co., Ltd., Tokyo, Japan;
†Department of Cardiology, the Marc and Ruti
e, New York, New York; ‡‡Biomedical NMR,
, Eindhoven, the Netherlands; and the §§Centro
estigation was partially supported by the Fondation
01 HL071021 (Dr. Fisher), and R01 HL078667
d by Daichii Sankyo Inc. Drs. Tanimoto, Brown,
ents via University of California San Diego for
Amarin; and holds equity interest Atherotope. Dr.
l other authors have reported that they have no
MD, served as Guest Editor for this paper.ork;
cine
nity
¶ Div
* ia; †
B icin
D logy
N s inv
L BI R
a ovide
a pat
o , and
F . Al
r sas,B B R E V I A T I O N S
N D A C R O N YM S
ABCA1 ATP-binding casse
transporter A1
a.u. arbitrary units
UC area under the curve
T computed tomograph
CE-CMR dynamic contra
nhanced cardiac magnetic
esonance
DG fluorodeoxyglucose
XR liver X receptor
ET positron emission
omography
UV standard uptake valu
EGF vascular endothelia2011, accepted November 30, 2011.
ab
a
w
m
o
t
d
w
a
m
a
aphy
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 5 , N O . 8 , 2 0 1 2
A U G U S T 2 0 1 2 : 8 1 9 – 2 8
Vucic et al.
LXR Agonist Regresses Inflammation in Atheroma
821Three baseline age-matched animals on chow diet
served as nonatherosclerotic controls at baseline and
underwent PET/CT and macrophage histological
staining for correlation between standard uptake
value (SUV) and macrophage density. Diets were
prepared by Research Diet Inc. (New Brunswick,
New Jersey). All imaging and surgical procedures
were performed with the animals under anesthesia
by intramuscular injection of ketamine (20 mg/kg,
Fort Dodge Animal Health, Fort Dodge, Iowa) and
xylazine (5 mg/kg, Bayer HealthCare Pharmaceu-
ticals, Wayne, New Jersey). The protocol was ap-
proved by the Mount Sinai School of Medicine
Institute Animal Care and Use Committee.
Blood analysis and immunohistology. See Online
Appendix.
18F-FDG–PET/CT. PET images were acquired using a
combined PET/CT scanner (Discovery LS, GE
Healthcare, Milwaukee, Wisconsin). After injec-
tion of 37 MBq (1 mCi/kg) of 18F-FDG, 3 h were
llowed for the 18F-FDG to circulate to lower
18F-FDG blood activity. Subsequently, a non–
contrast-enhanced CT scan was performed for at-
tenuation correction and anatomic localization of
the PET signal. PET images were acquired for 10
min in a 3-dimensional mode. The acquisition
High Cholesterol Diet
Balloon injury at 2 and 6 weeks
(n = 21)
Lipid Profile PET/CT
DCE-MRI
MC-MRI
Lipid Profile
ABCAI-
mRNA
L
Baseline
0 4
Figure 1. Study Design
Atherosclerotic New Zealand white rabbits after 4 months of a high
were performed (baseline). Animals were then divided into control,
and at 7 months (3-month imaging), imaging scans, lipid proﬁles, R
formed. After last imaging, all animals were immediately sacriﬁced
transporter A1; DCE-CMR  dynamic contrast-enhanced cardiac ma
nance; PET/CT  positron emission tomography/computed tomogrcovered the area from the diaphragm to the iliacbifurcation. Image reconstruction was performed
using a Fourier iterative algorithm, giving a final
reconstructed slice thickness of 4.25 mm.
PET/CT image analysis. PET/CT data were analyzed
y an experienced observer blinded to the histology
nd CMR results, using a GE Healthcare Xeleris
orkstation. PET/CT outcome variables were the
aximum and average SUVs. SUVs were recorded
n contiguous axial slices in the aorta, starting from
he left renal artery and to the iliac bifurcation, by
rawing circular regions of interest encompassing the
hole visible vessel wall. An average of 15 slices per
nimal were analyzed. The average maximum and
ean SUV (SUVmax and SUVmean, respectively) per
nimal were used in the statistical analysis.
Anatomic and DCE-CMR. Rabbits were imaged using
a 1.5-T clinical CMR system (Siemens Sonata,
Siemens Medical Solutions USA, Inc., Malvern,
Pennsylvania) using a conventional knee coil for
signal reception. T1-, T2-, and proton density–
weighted images were acquired from the left renal
artery to the iliac bifurcation to characterize athero-
sclerotic plaques (17).
DCE-CMR was acquired on 1 selected axial slice
using a black blood turbo spin echo after injection
of 0.2 mmol/kg of gadopentetate dimeglumine
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822This sequence was previously validated against his-
tology and demonstrated excellent reproducibility
(14,15,17).
Anatomic multicontrast CMR and DCE-CMR analysis.
The average vessel wall area was quantified by
manual tracing of the vessel wall contours on
contiguous T2-weighted slices of the aorta between
the left renal artery and iliac bifurcation using
VesselMass software (Leiden University Medical
Center, Leiden, the Netherlands).
DCE-CMR data were analyzed using custom
Matlab (MathWorks, Natick, Massachusetts) soft-
ware. The area under the signal intensity versus
time curve of a region of interest encompassing the
whole aortic wall visible in the slice acquired at 1
and 2 min after contrast agent injection was calcu-
lated (17). All CMR and DCE-CMR measurements
were performed by independent operators blinded to the
results of PET and immunohistology.
Statistical analysis. Continuous DCE-CMR and
ET/CT outcomes were modeled as linear func-
ions of time by using a linear mixed model; to
djust for multiple comparisons, we used the
onferroni-Holm step-down procedure (14,18).
ll statistical analyses were performed using Proc
ixed in SAS Version 9.2 (SAS Institute, Cary,
orth Carolina). All histological data, animal char-
cteristics data, and nonlinear regression imaging
Table 1. Animal Characteristics
Control (n  6) Atorvastatin (n
Weight, kg
4 months 3.42 0.33 3.51 0.2
5 months 3.48 0.31 3.47 0.3
7 months 3.50 0.30 3.62 0.3
Total cholesterol, mg/dl
4 months 1,099 315 1,278 19
5 months 1,158 282 850 43
7 months 1,124 200 843 27
Triglycerides, mg/dl*
4 months 184 110 180 19
5 months 113 95 163 80
7 months 172 163 161 88
Glucose, mg/dl
4 months 140 27 121 12
5 months 178 40 169 41
7 months 180 47 201 53
Insulin, mg/dl
4 months 0.58 0.38 0.42 0.1
5 months 0.28 0.06 0.38 0.1
7 months 0.21 0.14 0.27 0.0
Values are mean  SD. Fasting values for total cholesterol, triglycerides, glucos
of p for the 3 groups are shown in separate columns. *Indicates nonfasting.
A  atorvastatin; C  control; R  R211945.ata were analyzed with a 2-tailed Student t test.
umerical values are expressed as mean SD. Values of
 0.05 were considered significant.
R E S U L T S
Animal characteristics and serum analysis. All ani-
mals exhibited significantly elevated total choles-
terol levels after 4 months on a high-fat diet (Table 1).
The total cholesterol level of the control and
R211945-treated groups did not change, whereas
the atorvastatin group showed a reduction of 33% at
1 month and 34% at 3 months of treatment
compared with baseline (Table 1). Weight and
nonfasting triglyceride levels were not different
between the groups (Table 1). Therapeutic plasma
levels of both R211945 and atorvastatin were de-
tected at 1 and 3 months by mass spectrometry
(data not shown).
R211945 regresses inﬂammation and atorvastatin
arrests inﬂammation progression as assessed by
18F-FDG–PET/CT. On completion of baseline 18F-
FDG–PET/CT imaging, animals were divided into
3 matched groups (control, atorvastatin, and R211945)
and subsequently imaged at 1 and 3 months (Fig. 2).
The individual groups displayed similar baseline
average SUVmax (0.64  0.05, 0.63  0.09, and
.64  0.09, respectively) and identical SUVmean
6) R211945 (n  6) p Value (C/A) p Value (C/R)
3.49 0.21 0.59 0.63
3.48 0.26 0.95 0.97
3.60 0.21 0.49 0.49
1,228 223 0.41 0.49
1,187 169 0.11 0.85
1,119 142 0.04* 0.97
163 75 0.97 0.79
129 102 0.41 0.82
158 89 0.91 0.87
156 41 0.23 0.49
182 52 0.68 0.87
173 27 0.48 0.81
0.47 0.37 0.48 0.72
0.29 0.13 0.14 0.85
0.23 0.06 0.43 0.83
d insulin and weight for the control, atorvastatin, and R211945 groups. Values
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823(0.54  0.05, 0.54  0.09, and 0.54  0.08,
respectively) (Fig. 2). By using a linear mixed model
and adjusting for multiple comparisons, we found
that the SUVs of control animals showed significant
differences compared with R211945-treated ani-
mals at 3 months after therapy initiation for both
SUVmax (p  0.0007) and SUVmean (p  0.0001).
On treatment, the SUV versus time slope for the
R211945-treated group was negative and statisti-
cally different from zero for both SUVmax and
SUVmean (p  0.001 and p  0.0009, respectively),
ndicating regression. In comparison, SUVmax and
SUVmean versus time slopes for the atorvastatin-
treated group were not statistically different from
zero (p  0.60 and p  0.37, respectively), indi-
cating halting of progression. In contrast, the SUV
versus time slope for the control group was positive:
SUVmax (p  0.04) and SUVmean (p  0.01),
indicating progression. A significant difference in
the slopes of R211945-treated group from those of
the control group for both SUVmax (p  0.0004)
nd SUVmean (p  0.0001) was detected. Figure 2
shows scatterplots and the SUVs versus time slopes.
Figure 2. 18F-Flurodeoxyglucose–PET/CT
(A to I) Coronal PET images through the abdominal aorta (white ar
of all groups (control, atorvastatin, and R211945, respectively). (B, E
at 3 months. Summary showing scatterplots and standard uptake vThere was a significant interaction between timeand group (p 0.0016 for SUVmax and p 0.0003
or SUVmean).
R211945 does not change neovascularization, whereas
atorvastatin shows a trend toward a decrease in neo-
vascularization assessed by DCE-CMR. Figure 3 shows
rea under the curve (AUC) maps from 1 represen-
ative rabbit from each group and the mean AUC
-min values over time. The AUC versus time slope
or the R211945 group was negative but not statis-
ically different from zero (AUC1 min, p  0.14;
AUC
2 min
; p  0.10) (Fig. 3). The AUC versus time
lope for the atorvastatin-treated group was nega-
ive and trended toward a significant difference
rom zero (AUC1 min, p  0.06; AUC2 min; p 
0.06). The AUC versus time slope for the control
group was not statistically different from zero for
AUC measures (AUC1 min, p  0.40; AUC2 min,
 0.20). There was no significant interaction
etween time and group (p 0.6350 for AUC1 min;
p  0.8011 for AUC2 min).
R211945 and atorvastatin have no effect on vessel wall
area as assessed by multicontrast CMR. Multicontrast
CMR revealed no significant changes in aortic wall
heads) from 1 representative animal per group. (A, D, G) Baseline
All groups at 1 month. (C, F, I) All groups
s versus time slopes (bottom). Abbreviations as in Figure 1.row
, H)area in either group (Fig. 4).
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824R211945 and atorvastatin decrease macrophages, apo-
lipoprotein B, and oxidized phospholipids in plaque.
Aortic tissue analysis of the individual groups (Figs. 5
and 6) showed a significantly lower macrophage
density in the R211945 and atorvastatin groups
compared with the control group (0.22  0.009,
0.217  0.02, and 0.32  0.009 [arbitrary units
(a.u.)], respectively; p  0.0001 and p  0.0004,
espectively). A significantly lower apolipoprotein B
ensity was detected in the R211945 and atorvasta-
in groups compared with the control group (0.25 
.05, 0.26  0.07, and 0.33  0.03 [a.u.], respec-
ively; p  0.01 and p  0.04, respectively).
211945 treatment resulted in a 42% reduction in
xidized phospholipid density compared with the control
roup (0.076 0.026 and 0.146 0.045 [a.u.], respec-
ively, p 0.02), whereas atorvastatin treatment led to a
eduction of 23% in oxidized phospholipid density
0.106  0.026, p 0.08 vs. control). Average smooth
uscle actin density was very similar between the
211945, atorvastatin, and control groups (0.24 
Figure 3. DCE-CMR
(A to I) Single-slice axial T1-weighted CMR with color-coded overlay
the aorta. (A, D, G) All groups at baseline (control, atorvastatin [Ato
(C, F, I) All groups at 3 months. Warm colors (orange to red) indica
indicate lower AUCs. Summary showing scatterplots and AUCs vers.075, 0.26  0.078, and 0.27  0.078 [a.u.], respec-ively; p 0.36 and p 0.23, respectively vs. control). A
rend toward lower neovessel content was observed in the
211945- and atorvastatin-treated groups (p 0.12 and
 0.12, respectively, vs. control).
D I S C U S S I O N
We demonstrate that the LXR agonist R211945
significantly regresses inflammation in plaques of
atherosclerotic rabbits as quantified by 18F-FDG–
ET/CT. Furthermore, with DCE-CMR, we ob-
erved a trend toward a decrease in neovasculariza-
ion with atorvastatin treatment. The imaging
esults were confirmed by histological analysis and
orrelation assessment between imaging parameters
nd tissue macrophage density and neovessel con-
ent, respectively (Online Fig. 1).
The potential to noninvasively monitor plaque
nflammation and its changes after therapeutic in-
ervention by using 18F-FDG–PET/CT and DCE-
CMR has been shown in multiple studies (19–21).
the contrast signal at 1 min of the abdominal aorta with insert of
, and R211945, respectively). (B, E, H) All groups at 1 month.
igher areas under the curve (AUCs); cool colors (green to blue)
me slopes (bottom). Abbreviations as in Figure 1.of
rva]
te hWe recently demonstrated in the same animal
u
d
are
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825model used here the capability of both imaging
modalities (18F-FDG–PET/CT and DCE-CMR)
to assess the reduction in inflammation and neo-
vascularization after pharmacological intervention
(14,16). Atorvastatin treatment led in the current
study to an arrest in the increase in 18F-FDG
ptake, whereas R211945 induced a significant
ecrease in 18F-FDG uptake over time.
Figure 4. MC-CMR
Single-slice axial T2-weighted representative CMR with insert of the
All groups at baseline (control, baseline atorvastatin [Atorva], and b
(C, F, I) All groups at 3 months. Bar graph summary (right). Values
Figure 5. Immunohistology
Representative immunohistological images of individual groups of the
macrophages (A, E, I), apolipoprotein B (ApoB) (B, F, J), oxidized ph
are shown. Objective magniﬁcation: 10. The lumen is on the right-hanHistological analysis revealed a similar macro-
phage density in both the R211945 and atorvastatin
groups, whereas only the R211945 group showed a
significant decrease in SUVs, which was surprising
because one would expect a lower macrophage
content in the R211945 group given the observed
decrease in SUVs. One potential interpretation is
a difference in the inflammatory state of the
ta with T2-, T1-, and proton density weighing (A to I). (A, D, G)
ine R211945, respectively). (B, E, H) All groups at 1 month.
mean  SD. Abbreviations as in Figure 1.
ominal aorta at 3 months. Staining (red-brown, red arrowheads) for
holipids (OxPL) (C, G, K), and smooth muscle actin (SMA) (D, H, L)aor
aselabd
ospd side from the tissue.
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826residual vessel wall macrophages because 18F-
DG uptake by macrophages is closely linked to
heir state of activation (22). Interestingly, we
bserved a greater magnitude of oxidized phos-
holipid reduction in the R211945 group com-
ared with the atorvastatin group. Lipid oxida-
ion in plaque occurs partially through direct
ction of activated macrophages (23).
Furthermore, effects on smooth muscle cells,
ndothelial cells, T cells, and the modulation of
ypoxia may have been induced by R211945, lead-
ng to a more pronounced decrease in SUVs com-
ared with atorvastatin (24).
Noninvasive DCE-CMR demonstrated a trend
n reduction of neovascularization in the atorvasta-
in group. Our results are consistent with human
nd animal studies in which atorvastatin treatment
esults in neovessel regression via suppression of
ascular endothelial growth factor (VEGF) (25,26).
his result is, furthermore, consistent with that our
revious study in which a reduction in neovasculariza-
ion after treatment with the peroxisome proliferator–
ctivated receptor gamma agonist pioglitazone was
bserved (14). Peroxisome proliferator–activated
eceptor gamma agonists, similar to statins, de-
rease neovascularization (27). In contrast, the
211945-treated group did not show a significant
Figure 6. Summary Immunohistology
(Left) Macrophages (MAC), ApoB, OxPL, and SMA staining at 3 mon
shows CD-31 staining for neovessels (individual p values between c
histological images after CD-31 staining for neovessels: control (A),
*p  0.05; ***p  0.001. n.s.  nonsigniﬁcant; control versus treatmeduction in neovasculature. The short-term appli- ration of an LXR agonist, in contrast to atorvastatin
nd pioglitazone, has been shown to induce VEGF
28). The pathophysiological role of LXR-induced
EGF is unclear at the moment. VEGF, however,
s not only important in angiogenesis but is critical
or the resolution of injury (29). In addition, we did
ot assess VEGF or target tissue VEGF-receptor
xpression directly in our study and, therefore,
annot conclusively determine the effects of the
XR agonist on VEGF.
Both atorvastatin and R211945 treatments did not
each statistical significance for both the imaging and
istological parameters, which can be explained by the
agnitude of the observed drug effect and the result-
ng power from the current sample size.
A potent induction of ABCA1 (Online Fig. 2)
as observed in the R211945 treatment group. The
reviously described triglyceride increase by LXR
gonists was absent in our study. Preliminary data
emonstrate that R211945 preferentially acts on
asculature versus liver and furthermore shows se-
ective nuclear cofactor recruitment, thereby limit-
ng transactivation of lipogenic genes and, as a
esult, avoiding hepatic and metabolic side effects.
From an imaging standpoint, we show the capabil-
ties of 18F-FDG–PET/CT and DCE-CMR to track
oninvasively therapeutic intervention in atheroscle-
in control and atorvastatin- and R211945-treated animals. Inset
rol and treatment group are indicated). (A to C) Representative
vastatin (B), and R211945 (C). All values are mean  SD.
t groups. Abbreviations as in Figure 5.ths
ont
atorotic disease. This study supports the complementary
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827role in future clinical applications of the 2 imaging
techniques given the established correlation between
18F-FDG–PET/CT and DCE-CMR with macro-
phages/inflammation and neovasculature, respectively.
Study limitations. Our animal model is an aortic
balloon injury model in combination with high cho-
lesterol diet. This model is characterized by significant
vascular inflammation and macrophage content,
which does not mimic chronic stages of atherosclerosis
in humans. Our response to R211945 treatment
therefore may not be transferrable to all stages of
atherosclerotic disease in humans. The standard up-
take values assessed with 18F-FDG-PET/CT may be
ependent not only in the inflammatory state but also
n hypoxia within the vessel wall, which was not
ssessed in our study. We performed DCE-CMR on
nly 1 selected axial slice and, therefore, the presented
esults rely on the matching of chosen slices between
he imaging sessions. Our experimental setup where
nimals were under anesthesia allowed for optimal
lice matching and this may not always be achievablelation 1989;79:8–15.
1
1
1
1
1
1
namic contrast enC O N C L U S I O N S
In summary, we demonstrate the induction of
regression of atherosclerosis in a rabbit model of
atherosclerosis by an LXR agonist without causing
lipogenic side effects. 18F-FDG–PET/CT and
CE-CMR were used in this study as markers of
ascular macrophage content/inflammation and neo-
ascularization. Both imaging techniques are nonin-
asive and clinically available, and this study has,
herefore, direct implications for the future assessment
f interventions in atherosclerotic disease.
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